Background: Many health care organizations offer pediatric infusions in outpatient infusion centers or, as in our organization, in a hospital-based outpatient Pediatric Infusion Therapy Center (PITC). When restrictions related to the COVID-19 pandemic decreased our PITC appointment capacity by 40%, other patient and family satisfaction issues were exacerbated. We implemented a new approach to pediatric infusions with the aim of improving patient and family satisfaction and reducing the amount of time in an appointment itinerary without negatively affecting patient safety. Methods: Our team used a phased approach to pilot the administration of short chemotherapy infusions in the same outpatient clinic examination rooms where consultation and routine office visits were conducted. Patients saw their specialist for an examination and, if clinically indicated, their infusion was administered in the same room. Appointment itineraries were then completed. The team tracked efficiency, satisfaction, and safety metrics related to the new process. Results: All efficiency metrics improved. No harm came to the 49 unique patients who received a total of 184 infusions. Patient appointment itineraries were shortened by an average of 1.03 hr. Satisfaction survey responses indicated a clear preference (93%) for the new process. Discussion: The novel approach of offering short infusions in outpatient clinic examination rooms provides an opportunity to ease capacity constraints and further increase patient and family satisfaction. This method may be especially helpful for health care organizations when external influences (e.g., lack of physical space, challenging patient volumes, and pandemics) necessitate a change.
BolsoverS. (2018). Introducing outpatient parenteral antimicrobial therapy in a children's hospital. Nursing Children and Young People, 30(1), 24–27. https://doi.org/10.7748/ncyp.2018.e974
4.
CorsiM. P.SheaK.KnoebelR. W. (2020). Impact of transitioning inpatient chemotherapy regimens to the outpatient setting. Journal of Oncology Pharmacy Practice, 26(6), 1324–1330. https://doi.org/10.1177/1078155219891566
5.
FeslerS. M.TomsR. (2020). Infusion center outpatient acuity: An integrative review of the literature. Journal of Pediatric Nursing, 55, 184–191. https://doi.org/10.1016/j.pedn.2020.08.018
6.
Ganesan, P., Mehra, N., Joel, A., Radhakrishnan, V., Dhanushkodi, M., Perumal Kalayarasi, J., Kannan, K., Ganesan, T. S., & Sagar T. G. (2019). Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory Hodgkin's lymphoma. Leukemia Research, 84, Article 106188. https://doi.org/10.1016/j.leukres.2019.106188
7.
Getz, K. D., Szymczak, J. E., Li, Y., Madding, R., Huang, Y. V., Aftandilian, C., Arnold, S. D., Bona, K. O., Caywood, E., Collier, A. B., Gramatges, M. M., Henry, M., Lotterman, C., Maloney, K., Mian, A., Mody, R., Morgan, E., Raetz, E. A., Rubnitz, J., … Aplenc, R. (2021). Medical outcomes, quality of life, and family perceptions for outpatient vs inpatient neutropenia management after chemotherapy for pediatric acute myeloid leukemia. JAMA Network Open, 4(10), Article e2128385. https://doi.org/10.1001/jamanetworkopen.2021.28385
8.
HutsellS. Q.WuM.ParkK. T. (2017). Frequency of severe infusion reactions associated with outpatient infusion of infliximab without premedications. Journal of Pediatric Gastroenterology and Nutrition, 65(4), 430–431. https://doi.org/10.1097/MPG.0000000000001535
9.
JonesR. L.MakiR. G.PatelS. R.WangG.McGowanT. A.ShalabyW. S., Knoblauch, R. E., von Mehren, M., & Demetri, G. D. (2019). Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer, 125(24), 4435–4441. https://doi.org/10.1002/cncr.32462
10.
JoswiakM. E. (2018). Transforming orientation through a tiered skills acquisition model. Journal for Nurses in Professional Development, 34(3), 118–122. https://doi.org/10.1097/NND.0000000000000439
11.
KellyK. P.WellsD. K.ChenL.ReevesE.MassE.CamittaB.HindsP. S. (2014). Caregiving demands and well-being in parents of children treated with outpatient or inpatient methotrexate infusion: A report from the children's oncology group. Journal of Pediatric Hematology Oncology, 36(6), 495–500. https://doi.org/10.1097/MPH.0b013e31828b0947
12.
MielkeD.WittigA.TeichgraberU. (2020). Peripherally inserted central venous catheter (PICC) in outpatient and inpatient oncological treatment. Support Care Cancer, 28(10), 4753–4760. https://doi.org/10.1007/s00520-019-05276-0
13.
MuellerI.EhlertK.EndresS.PillL.SiebertN.KietzS., Brock, P., Garaventa, A., Valteau-Couanet, D., Janzek, E., Hosten, N., Zinke, A., Barthlen, W., Varol, E., Loibner, H., Ladenstein, R., & Lode, H. N. (2018). Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. MAbs, 10(1), 55–61. https://doi.org/10.1080/19420862.2017.1402997
14.
OrmeL. M.BablF. E.BarnesC.BarnettP.DonathS.AshleyD. M. (2014). Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: A randomised trial. Pediatric Blood Cancer, 61(8), 1427–1433. https://doi.org/10.1002/pbc.25012
15.
YangH.HaoY.QiC. Z.ChaiX.WuE. Q. (2020). Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a U.S. Hospital's perspective. Journal of Managed Care Pharmacy, 26(8), 971–980. https://doi.org/10.18553/jmcp.2020.20052
16.
YusefD.GonzalezB. E.FosterC. B.GoldfarbJ.SaracusaC.WorleyS.SabellaC. (2017). Piperacillin-tazobactam-induced adverse drug events in pediatric patients on outpatient parenteral antimicrobial therapy. ThePediatric Infectious Disease Journal, 36(1), 50–52. https://doi.org/10.1097/INF.0000000000001351